Annual digital health cohort
An archived evidence-led selection of promising early-stage digital health ventures, published from 2022 to 2026.
Published by Galen Growth since 2022 and powered by HealthTech Alpha’s structured market intelligence.
Research archive
Compare how the analytical universe and selected cohorts have developed as digital health has matured.
2026 edition
The final edition drew from more than 55,000 companies and 1.5 billion structured data points. The selected cohort showed a 96% survival rate, $1.6 billion in funding, 1,001 partnerships, and 3,176 publications.
2025 edition
The 2025 edition evaluated more than 50,000 digital health companies. Its cohort demonstrated strong capital efficiency and ecosystem traction, with more than $1.5 billion raised and over 700 partnerships.
2023 edition
The 2023 edition assessed more than 14,000 ventures using funding, partnerships, scientific output, and commercial momentum to identify emerging global leaders.
2022 edition
The first HealthTech 250 assessed more than 12,500 ventures worldwide through HealthTech Alpha, highlighting breakout potential across financial, commercial, and scientific signals.
Evidence-led selection
Each edition applied structured signals to identify emerging ventures with evidence of momentum, not simply visibility.
The analysis started with HealthTech Alpha’s structured coverage of digital health ventures worldwide.
Funding, partnerships, publications, maturity, and commercial activity were assessed consistently.
Each edition selected 250 early-stage ventures demonstrating credible breakout potential.
Frequently asked questions
The HealthTech 250 was Galen Growth’s annual evidence-led selection of 250 promising early-stage digital health ventures worldwide.
Ventures were evaluated using HealthTech Alpha signals covering capital formation, partnerships, scientific output, maturity, and commercial momentum.
The cohort primarily focused on recently incorporated ventures, typically from Seed to Series A, that demonstrated meaningful strategic or financial traction.
HealthTech Alpha provided structured intelligence across global digital health companies, including funding rounds, partnerships, publications, evidence, and corporate activity.
No. It was an intelligence and benchmarking publication designed to identify emerging innovation signals and did not constitute investment advice.
The HealthTech 250 was a curated annual cohort. HealthTech Alpha was the intelligence platform and underlying data system used for scouting, benchmarking, and diligence. HealthTech Alpha is no longer available.